{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T09:09:29Z","timestamp":1760864969331},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,12,12]],"date-time":"2003-12-12T00:00:00Z","timestamp":1071187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> Terlipressin is a vasopressin analog that may improve renal function in hepatorenal syndrome by mechanisms as yet unknown. The authors investigated the effect of the drug on systemic, hepatic and renal hemodynamics in cirrhosis.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Six patients with cirrhosis and ascites were studied (five Child's B and one Child's C). Heart rate (HR), mean arterial pressure (MAP), cardiac output (CO), systemic vascular resistance (SVR), hepatic venous pressure gradient (HVPG), reverse thermodilution unilateral real\u2010time renal blood flow (RBF), urinary flow, and sodium concentrations were measured before and 1\u2003h after an intravenous bolus of 2\u2003mg of terlipressin.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Following terlipressin administration, HR fell significantly (84.2\u2003\u00b1\u20036 to 70.8\u2003\u00b1\u20034.9, <jats:italic>P<\/jats:italic>\u2003=\u20030.013), MAP increased (72.7\u2003\u00b1\u20033.6 to 87\u2003\u00b1\u20035.3\u2003mmHg, <jats:italic>P<\/jats:italic>\u2003=\u20030.027), CO fell (7.4\u2003\u00b1\u20030.8 to 6.4\u2003\u00b1\u20030.8\u2003L\/min, <jats:italic>P<\/jats:italic>\u2003=\u20030.02) and SVR increased (1368.5\u2003\u00b1\u2003236 to 2079.7\u2003\u00b1\u2003458, <jats:italic>P<\/jats:italic>\u2003=\u20030.04). There were no significant differences in HVPG (12.3\u2003\u00b1\u20031.6 to 14\u2003\u00b1\u20030.9\u2003mmHg, <jats:italic>P<\/jats:italic>\u2010value not significant [NS]), RBF (255\u2003\u00b1 0.02 compared with 249\u2003\u00b1\u20030.02\u2003mL\/min, <jats:italic>P<\/jats:italic>\u2010value NS), urinary volume (49.1\u2003\u00b1\u20038.9 compared with 49.6\u2003\u00b1\u200316.7\u2003mL\/\u2003h, <jats:italic>P<\/jats:italic>\u2010value NS) and urinary sodium excretion (4\u2003\u00b1\u20031.1 compared with 5.9\u2003\u00b1\u20033.5\u2003mmol\/\u2003h).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> In the present small study, the authors were able to demonstrate that a bolus injection of terlipressin produced an increase in MAP and SVR, along with a reduction in cardiac output without a reduction in renal blood flow. Further studies are necessary to define the effects of terlipressin on renal hemodynamics and sodium excretion.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2004.03226.x","type":"journal-article","created":{"date-parts":[[2003,12,12]],"date-time":"2003-12-12T12:03:35Z","timestamp":1071230615000},"page":"73-77","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: Pilot study"],"prefix":"10.1111","volume":"19","author":[{"given":"GEORGE","family":"THERAPONDOS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ADRIAN J","family":"STANLEY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PETER C","family":"HAYES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,12,12]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"IoannouG DoustJ RockeyDC.Terlipressin for acute esophageal variceal hemorrhage.Cochrane Database Syst. Rev.2001:CD002147."},{"key":"e_1_2_5_3_2","first-page":"268","article-title":"Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome","volume":"61","author":"Le Moine O","year":"1998","journal-title":"Acta Gastroenterol. Belg."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80158-0"},{"key":"e_1_2_5_5_2","first-page":"2113","article-title":"Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis","volume":"92","author":"Cervoni JP","year":"1997","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02088218"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200212000-00013"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35819"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200202000-00009"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.32364"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.5.664"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80151-7"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080532"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.1.90"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.26.12.1385"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2150"},{"key":"e_1_2_5_17_2","first-page":"1053","article-title":"[Successful conservative therapy of hepatorenal syndrome with vasopressin\u20101\u2010receptor antagonist ornipressin]","volume":"36","author":"Gulberg V","year":"1998","journal-title":"Z. Gastroenterol."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199402000-00032"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270107"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300430"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80456-4"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80297-2"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(91)90734-3"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2004.03226.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2004.03226.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T07:14:25Z","timestamp":1697354065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2004.03226.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1111\/j.1440-1746.2004.03226.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2004.03226.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,12,12]]},"assertion":[{"value":"2003-12-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}